ArticleFederal practitioner : for the health care professionals of the VA, DoD, and PHS2025
Radiation and Medical Oncology Perspectives on Oligometastatic Disease Treatment.
Article in Federal practitioner : for the health care professionals of the VA, DoD, and PHS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Curative Oligometastatic Radiation Therapy: Why We Should Redefine Intent When Cure May Be Attainable.Advances in radiation oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recent phase 2 randomized clinical trials support the use of aggressive local treatment in addition to systemic therapy for oligometastatic disease (OMD) to improve progression-free survival and overall survival. These studies have mostly incorporated stereotactic body radiotherapy and serve as the foundation for multiple phase 3 trials aiming to determine how many metastases comprehensive local radiotherapy (RT) offer survival benefits, and for which cancers. Methods: To understand clinician views on the role of local RT for OMD, a 12-question survey was developed that included case examples. The survey was distributed to Veterans Health Administration (VHA) radiation oncologists and medical oncologists. Results: Of 106 survey respondents, 59 (55.7%) were radiation oncologists and 47 (44.3%) were medical oncologists. All respondents indicated high-dose RT has potential benefits for appropriately selected cases. Most oncologists (88.7%) responded that RT for OMD contributes to cure (88.1% radiation oncologists, 89.4% medical oncologists; Conclusions: The results of this study highlight ongoing support among VHA oncologists for local RT in the management of OMD and reveal specialty-based and access-based variability in treatment perspectives.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.